中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2008年
5期
389-391
,共3页
王哲海%郭珺%陈阵%李长征%盛立军%周登光%刘波%刘杰%王庆才%张恩宁
王哲海%郭珺%陳陣%李長徵%盛立軍%週登光%劉波%劉傑%王慶纔%張恩寧
왕철해%곽군%진진%리장정%성립군%주등광%류파%류걸%왕경재%장은저
胃肿瘤%多西紫杉醇%奥沙利铂%5-氟尿嘧啶%化疗
胃腫瘤%多西紫杉醇%奧沙利鉑%5-氟尿嘧啶%化療
위종류%다서자삼순%오사리박%5-불뇨밀정%화료
Gastric neoplasms%Docetaxel%Oxaliplatin%5-fluorouracil%Chemotherapy
目的 探讨多西紫杉醇(DOC)联合奥沙利铂(L-OHP)和5-氟尿嘧啶(5-Fu)的DOF双周方案对晚期胃癌的临床疗效和毒副反应.方法 37例晚期胃癌患者均行锁骨下深静脉穿刺或外周肘正中静脉穿刺,置入单腔输液导管,经电脑输液泵控制5-Fu的输液速度.DOC 35 mg/m2, 静脉滴注1 h,第1天;L-OHP 85 mg/m2,静脉滴注2 h,第1天;甲酰四氢叶酸(LV) 200 mg/m2,静脉滴注2 h,第1天;5-Fu 1500 mg/m2,持续静脉滴注48 h,第1～2天.14 d为1个周期,至少应用3个周期进行疗效评估.结果 全组37例均可评价疗效,总有效率为67.6%,其中完全缓解率为27.0%,部分缓解率为40.5%.至肿瘤进展时间为9.2个月,中位生存期为13.7个月.在初次化疗的11例患者中,有效率为81.8%;在既往接受过化疗的26例患者中,有效率为61.5%.主要剂量限制性毒性反应为骨髓功能抑制,其中Ⅲ～Ⅳ度白细胞下降率为29.7%,无治疗相关性死亡. 结论 DOF双周方案是晚期胃癌的有效化疗方案,其毒副反应轻微,患者易于耐受,值得进一步研究.
目的 探討多西紫杉醇(DOC)聯閤奧沙利鉑(L-OHP)和5-氟尿嘧啶(5-Fu)的DOF雙週方案對晚期胃癌的臨床療效和毒副反應.方法 37例晚期胃癌患者均行鎖骨下深靜脈穿刺或外週肘正中靜脈穿刺,置入單腔輸液導管,經電腦輸液泵控製5-Fu的輸液速度.DOC 35 mg/m2, 靜脈滴註1 h,第1天;L-OHP 85 mg/m2,靜脈滴註2 h,第1天;甲酰四氫葉痠(LV) 200 mg/m2,靜脈滴註2 h,第1天;5-Fu 1500 mg/m2,持續靜脈滴註48 h,第1～2天.14 d為1箇週期,至少應用3箇週期進行療效評估.結果 全組37例均可評價療效,總有效率為67.6%,其中完全緩解率為27.0%,部分緩解率為40.5%.至腫瘤進展時間為9.2箇月,中位生存期為13.7箇月.在初次化療的11例患者中,有效率為81.8%;在既往接受過化療的26例患者中,有效率為61.5%.主要劑量限製性毒性反應為骨髓功能抑製,其中Ⅲ～Ⅳ度白細胞下降率為29.7%,無治療相關性死亡. 結論 DOF雙週方案是晚期胃癌的有效化療方案,其毒副反應輕微,患者易于耐受,值得進一步研究.
목적 탐토다서자삼순(DOC)연합오사리박(L-OHP)화5-불뇨밀정(5-Fu)적DOF쌍주방안대만기위암적림상료효화독부반응.방법 37례만기위암환자균행쇄골하심정맥천자혹외주주정중정맥천자,치입단강수액도관,경전뇌수액빙공제5-Fu적수액속도.DOC 35 mg/m2, 정맥적주1 h,제1천;L-OHP 85 mg/m2,정맥적주2 h,제1천;갑선사경협산(LV) 200 mg/m2,정맥적주2 h,제1천;5-Fu 1500 mg/m2,지속정맥적주48 h,제1～2천.14 d위1개주기,지소응용3개주기진행료효평고.결과 전조37례균가평개료효,총유효솔위67.6%,기중완전완해솔위27.0%,부분완해솔위40.5%.지종류진전시간위9.2개월,중위생존기위13.7개월.재초차화료적11례환자중,유효솔위81.8%;재기왕접수과화료적26례환자중,유효솔위61.5%.주요제량한제성독성반응위골수공능억제,기중Ⅲ～Ⅳ도백세포하강솔위29.7%,무치료상관성사망. 결론 DOF쌍주방안시만기위암적유효화료방안,기독부반응경미,환자역우내수,치득진일보연구.
Objective To evaluate the efficacy and toxicity of a biweekly DOF regimen consisting of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer. Methods The biweekly DOF regimen was administered in 37 advanced gastric cancer patients. Docetaxel, oxaliplatin and leucovorin were given intravenously at a dose of 35 mg/m2, 85 mg/m2 and 200 mg/m2 for 1 h, 2 h and 2 h on D1, respectively, and 5-Fu was administered as continuous intravenous infusion for 48 h at a dose of 1500 mg/m2 on D1 and D2. This regimen was repeated every 2 weeks. The efficacy and toxicity were evaluated after completion of 3 cycles at least. Results The overall response rate (RR) of this series was 67.6%, complete response rate and partial response rate were 27.0% and 40.5%, respectively. The time to progression (TTP) was 9.2 months, and median survival time (MST) was 13.7 months. The RRs of 11 chemotherpy-nave patients and 26 patients pre-treated with chemotherapy were 81.8% and 61.5%, respectively. Conclusion Our preliminary results showed that this biweekly combination regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin is effective and tolerable for advanced gastric cancer. However, further investigation of this regimen is mandatory.
